Original Report

Quality of life after surgery for pleural malignant mesothelioma – methodological considerations


 

Background There is a dearth of literature on patient quality of life (QoL) after treatment for malignant pleural mesothelioma (MPM).

Objectives To review the literature on QoL after surgery for MPM and assess differences in quality of life between patients who have extrapleural pneumonectomy (EPP) and those who have pleurectomy and decortication (P-D).

Methods We retrieved and reviewed original research studies on quality of life after mesothelioma surgery. They had been published from January 1990 through June 2016, and included 15 articles and 12 datasets for a total of 523 patients.

Results QoL data was available for 102 EPP patients and 296 P-D patients. Two studies directly compared QoL outcomes between the 2 techniques. Symptoms, lung function parameters, and physical and social functioning were still compromised 6 months after surgery. However, P-D patients fared better than did EPP patients across QoL measures.

Limitations The amount of available literature is small, and the studies are heterogeneous.

Conclusions QoL is better for a longer period of time in patients who undergo P-D, compared with those who have EPP. Given the need for multimodality therapy for MPM and the aggressive nature of the disease, QoL outcomes should be strongly considered when choosing type of surgery for mesothelioma.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

VIDEO: Checkpoint inhibitors show few efficacy, safety differences
MDedge Hematology and Oncology
KRAS-targeted T-cell therapy derails metastatic cancer
MDedge Hematology and Oncology
Ganetespib fails to hit mark in phase III NSCLC trial
MDedge Hematology and Oncology
‘Vanishing’ role forecast for whole-brain irradiation for NSCLC metastases
MDedge Hematology and Oncology
VIDEO: Pivotal results nail osimertinib’s role in NSCLC
MDedge Hematology and Oncology
Pembrolizumab proves promising for treating advanced SCLC
MDedge Hematology and Oncology
Durvalumab could offer option for difficult-to-treat NSCLC
MDedge Hematology and Oncology
c-Myc could be key to alisertib potential in small-cell lung cancer
MDedge Hematology and Oncology
Toxicity high for SBRT in centrally-located lung tumors
MDedge Hematology and Oncology
VIDEO: Improved QOL an added benefit of pembrolizumab for NSCLC patients
MDedge Hematology and Oncology